Join us at today's @keystonesymposia.bsky.social Precision Genome Engineering conference, where we're presenting our latest #EpigeneticEditing advances at 7:30pm.

📣 ADDing a Lock to Epigenome Editing: DNMT3A Allostery Enhances Specificity and Potency of #CRISPR-CasX-based Epigenetic Repressors

Read the BiopharmaTrend article: www.biopharmatrend.com/news/scribe-...

Dive deeper into the science with our preprint: www.biorxiv.org/content/10.6...

@biorxivpreprint.bsky.social #CRISPR #Epigenetics #EpigeneticEditing

Scribe Therapeutics plans to test cholesterol-lowering epigenetic editing therapy The company’s lead program is an epigenetic silencing therapy designed to turn off genes without altering the underlying genetic code.

ICYMI learn more in @endpts.com about our plans to enter the clinic in mid-2026 with STX-1150, and our broader work to deliver on the potential of #CRISPR and nature’s blueprint for better cardiovascular health.

endpoints.news/scribe-thera...

#EpigeneticEditing #Epigenetics #HeartHealth #OurHearts

NEW PREPRINT: Introducing an additional regulatory layer for enhanced precision and potency in #CRISPR-CasX-based epigenetic medicine.

Press release and preprint links below 🧵

#EpigeneticEditing #Epigenetics

Happening TODAY at #JPM2026!

Don’t miss our CEO @benjaminloakes.bsky.social’s presentation at the J.P. Morgan Healthcare Conference (8:30 am PT) and panel on #biotech innovation at Fierce JPM Week (3:00 pm PT).

#JPM26 #CRISPR #GeneEditing #EpigeneticEditing #CVD

Coming up next week at #JPM2026:

Our CEO @benjaminloakes.bsky.social will speak at the J.P. Morgan Healthcare Conference and Fierce JPM Week. Don’t miss them on Wednesday, January 14 at 8:30 a.m. and 3:00 p.m. PT!

Links in 🧵 #CRISPR #GeneEditing #EpigeneticEditing #CVD

Our co-founder & CEO @benjaminloakes.bsky.social will present at the 44th Annual J.P. Morgan Healthcare Conference.

Join us on Wednesday, January 14 at 8:30 a.m. PT to hear what we have in store for 2026.

#JPM2026 #CRISPR #GeneEditing #EpigeneticEditing #CVD

Epigenetic editing: from concept to clinic - Nature Reviews Drug Discovery Epigenetic editing has emerged as a powerful hit-and-run approach to precise modification of gene expression without altering the underlying DNA sequence. This Review explores the therapeutic potentia...

Epigenetics Review - Epigenetic editing: from concept to clinic go.nature.com/3LZJjpi

Marianne G. Rots (University of Groningen) reporting in Nat Rev Drug Disc

#Epigenetics #Review #EpigeneticEditing
---

Gain deeper insights into gene regulation; epigenometech.com

Epigenetics Update - Cell-type- and locus-specific epigenetic editing of memory expression go.nature.com/4oCNoxu

Johannes Gräff (EPFL, Lausanne) reporting in Nat Genet

#Epigenetics #EpigeneticEditing #Memory
---

Discover the breakthrough at epigenometech.com

We’re headed to #ESGCT2025 to share our latest #CRISPR #EpigeneticEditing data. Check out our presentation on Thursday, Oct. 9!

🧬 Engineering enhanced epigenetic editors: novel repressor domains drive potent and durable therapeutic gene silencing in non-human primates

Epigenetics Update – Design of optimized epigenetic regulators for durable gene silencing with application to PCSK9 in nonhuman primates go.nature.com/4mPi3X7

#Epigenetics #GeneSilencing #EpigeneticEditing

---
Discover the breakthrough at epigenometech.com

With #CRISPR, we have the opportunity to move beyond treating symptoms to tackling the root causes of disease.

🎥 Watch the TEDx talk to see what the future of genetic medicine looks like: www.youtube.com/watch?v=RVde...

#GeneEditing #EpigeneticEditing

Getting to the Heart of CRISPR-Based Therapies Benjamin Oakes from Scribe Therapeutics shares how exciting advancements in CRISPR-based gene and epigenetic editing therapies impact the future of cardiovascular and cardiometabolic disease managemen...

💡 Read The Scientist's latest Innovation Spotlight interviewing our CEO @benjaminloakes.bsky.social about how next-generation #CRISPR #GeneEditing and #EpigeneticEditing tools are reshaping treatment for highly prevalent conditions like cardiometabolic disease.

www.the-scientist.com/getting-to-t...

PNAS Proceedings of the National Academy of Sciences (PNAS), a peer reviewed journal of the National Academy of Sciences (NAS) - an authoritative source of high-impact, original research that broadly spans...

Epigenetics Update - Fertile androgenetic mice generated by targeted epigenetic editing of imprinting control regions bit.ly/4niGVIi

Yanchang Wei (Shanghai Jiao Tong University) in PNAS

#Epigenetics #EpigeneticEditing #Imprinting #DNAme

---
Gain deeper insights with epigenometech.com

📊 #EpigeneticEditing: At EAS, our late-breaker spotlighted that Scribe’s novel epigenetic silencer, ELXR, achieves 9+ months of >50% LDL-C reduction in non-human primates ➡️ surpassing the current standard of care therapies for LDL-C lowering.

Epigenetics Update - A potent epigenetic editor targeting human PCSK9 for durable reduction of low-density lipoprotein cholesterol levels go.nature.com/4hvfHef

Research by Frederic Tremblay (Chroma Medicine) in Nat Med

#Epigenetics #EpigeneticEditing
---

Empower your research with epigenome.us

Gene-editing field sees another merger, this time between Chroma Medicine and Nvelop Therapeutics In industry parlance, the deal joins a “delivery” company with a “cargo” company — fusing the two key pieces needed to build a genetic medicine.

Like drug discovery, a company's journey is rarely, if ever, a straight line. Best of luck to former @chromamedicine
colleagues in this next phase of the journey to bring #epigeneticediting medicines to patients as
@nchromabio

www.statnews.com/2024/12/11/c...